Souhaitez-vous accéder aux communiqués récents ?

PTCE research presented at ADA 2026 found targeted pharmacist education helps overcome clinical inertia and supports evidence-based diabetes care.

PASO ROBLES, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- JUSTIN Vineyards & Winery has awarded new grants totaling more than $350,000 in support for nonprofit organizations and educators across...

Clofutriben improved HbA1c and other cardiometabolic parameters in patients with Type 2 diabetes in a 6-week, placebo-controlled, randomized Phase 2 trial  Subset of participants with elevated...

Homeless Vets Welcome Here: AI City Hall Project Moves on Omni-AI Microcities (Veterans First for America)

SHENZHEN, CHINA, June 08, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that the preclinical results of its self-developed innovative...

NEW ORLEANS, June 08, 2026 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, today announced results from a multi-center pivotal trial evaluating the safety and efficacy of the investigational twiist™...

MTRX31 led to a highly significant decrease in fat mass after two-months chronic dosing in a preclinical diet-induced obesity mouse model performed at thermoneutrality Weight loss and reduction of fat...

Company announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel...

Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance  New data expands on findings...